CME (AMA PRA Category 1 Credit)

  2. Home
  3. Credit Type
  4. CME (AMA PRA Category 1 Credit)
  5. Disease Area
Page 5 of 7
Results 301 - 375 of 454
No image set
U.S. Presidents with Severe Asthma: Endotypes and Precision Medicine
9833-0001-icon
Urgency for Early Diagnosis and Treatment of SMA
sma-journal-icon_263x0
Gene Therapy for SMA: An Emerging Treatment Option for a Devastating Disease
No image set
Reporting HRCT Findings for ILD from a Multidisciplinary Team
med-doc-aatd
A Closer Look at Alpha-1 Antitrypsin Deficiency: Peggy’s Story
med-doc-ph
How Pulmonary Arterial Hypertension Has Changed Iain’s Life
9834-0002
SMA: Data, Insights and Practice
9829-0001
From Bench to Bedside: Gene Therapy Approaches for Rare Diseases
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
9819-ntm case3
Management of Mycobacterium Abscessus Lung Disease
9819-ntm case2
Difficult to Treat Mycobacterium Avium Complex Lung Disease
9819-ntm case1
Management of Mycobacterium Avium Complex Lung Disease
9816-0001
The Latest from a Recent Pulmonary Conference in San Antonio
9816-0010
Updates in Inoperable CTEPH
9816-0009
The Importance of Early Integration of Palliative Care
9816-0006
Management of IPF Patients in 2018
9816-0005
Updates in the Diagnosis of ILD and the Role of Cryobiopsy
9816-00045
Overview of the Latest Clinical Trials in IPF
9816-0003
Evolution of Antifibrotic Therapy in IPF
9816-0002
Take Home Messages from the 2018 CHEST Annual Meeting
9816-0008
What We’re Learning from the IPF-PRO Registry
9816-0007
Comparing the 2017 Fleischner Society Guidelines and the 2018 ATS Guidelines
rePlace2
Emerging Treatments for NTM Lung Disease
rePlace2
Nontuberculous Mycobacteria Case 2: Alan
NTM_and_Treatment_Strategies_for_Patients_264x150
NTM and Treatment Strategies for Patients with Cavitary Disease
New_Findings_in_the_Treatment_of_MAC_264x150
New Findings in the Treatment of MAC Lung Disease
Why_You_Should_Pay_Attention_to_NTM_264x150
Why You Should Pay Attention to NTM Treatment Guidelines
Which_of_Your_Patients_Are_at_Risk_for_NTM_264x150
Which of Your Patients Are at Risk for NTM?
Practice_Improvement_through_ILD_Centers_264x150
Practice Improvement through ILD Centers and Community Partnerships
Improving_the_Care_for_IPF_Patients_264x150
Improving the Care for IPF Patients Using a Team-Based Approach
An_Early_Integrated_Palliative_Care_264x150
An Early Integrated Palliative Care Delivery Model for Patients with IPF
rePlace2
Treatment Challenges with MAC Lung Disease
rePlace2
Nontuberculous Mycobacteria: Summary
rePlace2
Treatment Challenges with MABC Lung Disease
rePlace2
Nontuberculous Mycobacteria Case 1: Maria
rePlace2
NTM – To Treat or Not to Treat
rePlace2
Goals of NTM Treatment
rePlace2
Guideline-recommended Treatments for NTM
rePlace2
Diagnosis of NTM
rePlace2
Factors Associated with Respiratory Involvement in NTM
rePlace2
Most Common Species in NTM Lung Disease
rePlace2
Nontuberculous Mycobacteria: Introduction and Epidemiology
9808-0004
What’s New in Spinal Muscular Atrophy? Reporting from Dallas
atopic-derm4
Atopic Dermatitis: Putting it Together (Dermatology)
atopic-derm3
Atopic Dermatitis: Putting it Together (Primary Care)
atopic-derm2 copy
Atopic Dermatitis: Recent and Emerging Therapies
atopic-derm1
An Introduction to Atopic Dermatitis
No image set
New Therapies, New Opportunities and New Challenges in Managing NTM
No image set
Updates in Inoperable CTEPH
9808-0003
SMA Updates from Los Angeles
pah icon
PAH Today: Mastering Current, Tailored Treatment
No image set
Achieving Better Control of Severe Asthma
asthma-uncontrol icon
A Personalized Approach to Managing Uncontrolled Asthma
9808-0002
Updates in SMA and Gene Therapy from Arlington, VA
Proper_Use_of_an_Inhaler_264x150
Proper Use of an Inhaler
biosims-archmed icon23
Top Questions about Biosimilars in Dermatology
biosims-archmed icon1
Top Questions about Biosimilars in Gastroenterology
biosims-archmed icon2
Top Questions about Biosimilars in Rheumatology
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
biosims-gastro2
Biosimilars and Patients with Inflammatory Bowel Disease
No image set
Nontuberculous Mycobacterial Lung Disease Today and Tomorrow
No image set
Exploring the Patient Journey with Problem-Based Learning
No image set
Genetics and Personalized Medicine for Patients with Pulmonary Fibrosis
No image set
Environmental Influences on the Development of Pulmonary Fibrosis
No image set
Gene Abnormalities and ILD
No image set
Exploring the Basic Mechanisms that Contribute to Development of Lung Fibrosis
No image set
Updates on Registry Enrollment and Growth of the Care Center Network
No image set
New Approaches to the Diagnosis of IPF
No image set
Exploring New Therapeutic Avenues for Managing PF
No image set
New Research on Mechanisms in the Development of PF
biosims-gastro1
Biosimilars: The New Era of Gastroenterology Management Considerations
No image set
Know Before You Go: IPF Grand Rounds Pre-learning
No image set
IPF Management Considerations
No image set
Perspectives on Side Effect Management
No image set
The Latest in IPF: Implications for Clinical Practice
Page 5 of 7

Search